[go: up one dir, main page]

ECSP088324A - 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas - Google Patents

2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas

Info

Publication number
ECSP088324A
ECSP088324A EC2008008324A ECSP088324A ECSP088324A EC SP088324 A ECSP088324 A EC SP088324A EC 2008008324 A EC2008008324 A EC 2008008324A EC SP088324 A ECSP088324 A EC SP088324A EC SP088324 A ECSP088324 A EC SP088324A
Authority
EC
Ecuador
Prior art keywords
amino
pyrido
pyrimidine
dihydro
compounds
Prior art date
Application number
EC2008008324A
Other languages
English (en)
Inventor
Paul A Barsanti
Nathan Brammeier
Paul Renhowe
Daniel J Poon
Teresa E Pick
Barry Haskell Levine
Christopher Mcbride
Cynthia Shafer
Timothy D Machajewski
William Antonios-Mccrea
Brandon M Doughan
Yi Xia
Maureen Mckenna
X Michael Wang
Kris Mendenhall
Yasheen Zhou
Baoqing Gong
Dan Gu
John Dolan
John Tulinsky
Kristin Brinner
Zhenhai Gao
Xiaodong Lin
Abran Costales
Alice Rico
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088324A publication Critical patent/ECSP088324A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Los compuestos revelados son 2-amino-7,8-dihidro-6H-pirido[4,3-d]pirimidina-5-uno, sus estereoisómeros, tautómeros, sales aceptadas farmacéuticamente, y pro-medicamentos de lo mismo; las composiciones que incluyen un portador farmacéuticamente aceptable y uno o más de los compuestos 2-amino-7,8-dihidro-6H-pirido[4,3-d]pirimidina-5-uno, ya sea solos o en combinación con por lo menos un agente terapéutico adicional. Se revelan los métodos de uso de los compuestos 2-amino-7,8-dihidro-6H-pirido[4,3-d]pirimidina-5-uno, ya sea solos o en combinación con por lo menos un agente terapéutico adicional, en la profilaxis o tratamiento de las enfermedades del sistema nervioso central, cardiovasculares, autoinmune, virales, y de proliferación celular.
EC2008008324A 2005-09-30 2008-03-28 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas ECSP088324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72279605P 2005-09-30 2005-09-30
US83688606P 2006-08-09 2006-08-09

Publications (1)

Publication Number Publication Date
ECSP088324A true ECSP088324A (es) 2008-04-28

Family

ID=37661234

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008324A ECSP088324A (es) 2005-09-30 2008-03-28 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas

Country Status (32)

Country Link
US (2) US7671059B2 (es)
EP (1) EP1928875B1 (es)
JP (2) JP5036002B2 (es)
KR (1) KR101311757B1 (es)
AR (1) AR058072A1 (es)
AT (1) ATE514694T1 (es)
AU (1) AU2006297124B2 (es)
BR (1) BRPI0616701A2 (es)
CA (1) CA2624253C (es)
CR (1) CR9846A (es)
CY (1) CY1112028T1 (es)
DK (1) DK1928875T3 (es)
EA (1) EA016152B1 (es)
EC (1) ECSP088324A (es)
GE (1) GEP20115231B (es)
HK (1) HK1118823A1 (es)
HR (1) HRP20110655T1 (es)
IL (1) IL190446A0 (es)
JO (1) JO2783B1 (es)
MA (1) MA29885B1 (es)
ME (1) ME01952B (es)
MY (1) MY143604A (es)
NO (1) NO342258B1 (es)
NZ (1) NZ566914A (es)
PE (1) PE20070621A1 (es)
PL (1) PL1928875T3 (es)
PT (1) PT1928875E (es)
RS (1) RS51795B (es)
SM (1) SMAP200800029A (es)
TN (1) TNSN08143A1 (es)
TW (1) TWI373471B (es)
WO (1) WO2007041362A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN101225083A (zh) * 2007-01-16 2008-07-23 北京摩力克科技有限公司 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
MX2010008269A (es) * 2008-02-01 2011-02-21 Takeda Pharmaceutical Inhibidores de hsp90.
US8759010B2 (en) 2008-09-26 2014-06-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Host cell kinases as targets for antiviral therapies against HCV infection
JP2012510444A (ja) * 2008-11-28 2012-05-10 ノバルティス アーゲー 治療的処置のためのＨｓｐ９０阻害剤
EP2370103B1 (en) * 2008-11-28 2016-03-23 Novartis AG Pharmaceutical combinations comprising an isoxazole derived hsp90-inhibitor and the her2 inhibitor trastuzumab
MA32934B1 (fr) * 2008-11-28 2012-01-02 Novartis Ag Combinaisons inhibitrices hsp90
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
NZ630860A (en) 2009-10-29 2016-03-31 Genosco Bissubstituted pyrido[4,3-d]-pyrimindin-5-one kinase nhibitors and medical uses
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
BR112014008400A2 (pt) 2011-10-14 2017-04-04 Novartis Ag derivados de 2-carboxamida cicloamino ureia em combinação com os inibidores de hsp90 para o tratamento de doenças proliferativas
ITTO20111013A1 (it) 2011-11-03 2013-05-04 Dac Srl Composti farmaceutici
CN103664938A (zh) * 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 含有嘧啶并环的syk抑制剂
US20150290204A1 (en) 2012-11-07 2015-10-15 Novartis Ag Combination therapy
US9677907B2 (en) * 2013-03-14 2017-06-13 Itron Inc Intelligent receptacle
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
PT3053578T (pt) * 2013-09-30 2021-02-09 Taiho Pharmaceutical Co Ltd Terapêutica de combinação de cancro usando composto de azabiciclo
BR112017003651A2 (pt) * 2014-09-02 2017-12-05 Pf Medicament derivados de isoquinolinona úteis no tratamento de câncer
KR20160035411A (ko) * 2014-09-23 2016-03-31 주식회사 오스코텍 LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
KR101653560B1 (ko) * 2016-02-02 2016-09-12 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
RU2629599C1 (ru) * 2016-09-28 2017-08-30 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ химиолучевого лечения опухолей прямой кишки и анального канала
CN115916752A (zh) * 2020-06-26 2023-04-04 日本农药株式会社 芳基四氢吡啶衍生物或其盐类、和含有该化合物的杀虫剂及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6165873A (ja) 1984-09-07 1986-04-04 Mitsui Petrochem Ind Ltd ２−ピペラジノピリミジン誘導体
CA1307786C (en) * 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
IL85347A0 (en) 1987-02-11 1988-07-31 May & Baker Ltd Cyclic diones
IL156872A0 (en) * 2001-02-12 2004-02-08 Hoffmann La Roche 6-substituted pyrido-pyrimidines
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
WO2006045096A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US20100152206A1 (en) * 2005-01-07 2010-06-17 Ralph Mazitschek Bicyclic Dihydropyrimidines and Uses Thereof
US20070027150A1 (en) * 2005-04-14 2007-02-01 Bellamacina Cornelia R 2-Amino-quinazolin-5-ones

Also Published As

Publication number Publication date
ME01952B (en) 2011-12-31
CR9846A (es) 2008-08-01
NZ566914A (en) 2011-09-30
EA200800992A1 (ru) 2008-10-30
KR101311757B1 (ko) 2013-09-26
NO342258B1 (no) 2018-04-30
JP5036002B2 (ja) 2012-09-26
HK1118823A1 (es) 2009-02-20
TNSN08143A1 (en) 2009-07-14
EA016152B1 (ru) 2012-02-28
TW200728304A (en) 2007-08-01
JP2012158611A (ja) 2012-08-23
TWI373471B (en) 2012-10-01
PT1928875E (pt) 2011-09-06
AR058072A1 (es) 2008-01-23
US20100004237A1 (en) 2010-01-07
JP2009510108A (ja) 2009-03-12
HRP20110655T1 (hr) 2011-10-31
US7671059B2 (en) 2010-03-02
CA2624253A1 (en) 2007-04-12
AU2006297124A1 (en) 2007-04-12
ATE514694T1 (de) 2011-07-15
DK1928875T3 (da) 2011-10-03
CY1112028T1 (el) 2015-11-04
NO20082069L (no) 2008-06-09
EP1928875A1 (en) 2008-06-11
US20070123546A1 (en) 2007-05-31
PL1928875T3 (pl) 2011-11-30
MY143604A (en) 2011-06-15
RS51795B (en) 2011-12-31
GEP20115231B (en) 2011-06-10
KR20080057318A (ko) 2008-06-24
AU2006297124B2 (en) 2011-12-08
SMP200800029B (it) 2008-05-07
CA2624253C (en) 2015-06-16
JO2783B1 (en) 2014-03-15
PE20070621A1 (es) 2007-09-06
EP1928875B1 (en) 2011-06-29
IL190446A0 (en) 2008-11-03
BRPI0616701A2 (pt) 2011-06-28
SMAP200800029A (it) 2008-05-07
WO2007041362A1 (en) 2007-04-12
MA29885B1 (fr) 2008-10-03

Similar Documents

Publication Publication Date Title
ECSP088324A (es) 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
EP1545545A4 (en) COMPOUNDS WITH THE BICYCLO 4.2.1 NONAN SYSTEM FOR THE TREATMENT OF FLAVIVIRIDAE / I INFECTIONS
MY145447A (en) Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
UY27729A1 (es) Inhibidores de quinasas.
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
CL2008002852A1 (es) Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
BRPI0616630B8 (pt) compostos de pirazol substituídos
UY29246A1 (es) Nuevos compuestos
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
ECSP045410A (es) Nuevos derivados de piridazin-3(2h)-ona
ECSP066474A (es) Arilindenopiridinas y arilindenopirimidinas y su uso como antagonista del receptor adenosina a2a
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
CO6382131A2 (es) Derivados de tieno [3,2-c]piridina como inhibidores de quinasas para el uso en el tratamiento del cáncer
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
NO20054405L (no) Kjemokinreseptor-binende heterosykel
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.